What Happened?
Shares of medical device company Zimmer Biomet (NYSE: ZBH) fell 10.2% in the afternoon session after the company reported underwhelming first quarter 2025 results as it lowered its full-year EPS guidance. A key takeaway was the weak growth. Sales were up just 1% as demand for some product lines came in weaker. While hips and trauma gear did well, others, like bone cement and surgical tools, dropped nearly 5%. Overall, this was a softer quarter.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Zimmer Biomet? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Zimmer Biomet’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Zimmer Biomet and indicate this news significantly impacted the market’s perception of the business.
Zimmer Biomet is down 11.9% since the beginning of the year, and at $92.04 per share, it is trading 24.2% below its 52-week high of $121.44 from May 2024. Investors who bought $1,000 worth of Zimmer Biomet’s shares 5 years ago would now be looking at an investment worth $779.78.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
